FOLH1 and neoplasm: In terms of the future development of PSMA-targeting ligands, there is an emerging trend to design and develop PSMA-targeting ligands that enable diagnosis and therapy with the same ligand, which could avoid discontinuity in diagnostic integration and tumour uptake or PK differences owing to ligand replacement.